Drug Resistance in Leishmania tropica and Treatment Failure in Iran
Author Information
Author(s): Hadighi Ramtin, Mohebali Mehdi, Boucher Patrick, Hajjaran Homa, Khamesipour Ali, Ouellette Marc
Primary Institution: Tehran University of Medical Sciences
Hypothesis
Is the clinical unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis correlated with the susceptibility of Leishmania parasites?
Conclusion
Parasites isolated from patients with non-healing lesions are frequently resistant to meglumine antimoniate, the first line of treatment in Iran.
Supporting Evidence
- 185 parasite isolates were collected from patients with cutaneous leishmaniasis.
- 10.8% of patients did not respond to the first course of treatment.
- Parasites from non-responders had EC50 values at least 4-fold higher than those from responders.
Takeaway
Some germs that cause skin infections in Iran are not getting better with the usual medicine because they have become strong against it.
Methodology
In vitro susceptibility testing was performed on 185 isolated parasites using a mouse macrophage model, and the correlation between clinical outcomes and EC50 values was analyzed.
Limitations
The study did not explore the long-term effects of treatment or the exact molecular mechanisms of resistance.
Participant Demographics
Patients aged 20 to 45 years from Mashhad, Iran, with confirmed cutaneous leishmaniasis.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website